Last reviewed · How we verify
American Genomics, LLC — Portfolio Competitive Intelligence Brief
1 marketed
0 filed
1 Phase 3
0 Phase 2
0 Phase 1
Live · 30-min refresh
Portfolio leaders (marketed + Phase 3 / filed)
| Drug | Generic | Phase | Class | Target | Area | First approval |
|---|---|---|---|---|---|---|
| Proparacaine Ophthalmic | Proparacaine Ophthalmic | marketed | Local anesthetic (ester) | Voltage-gated sodium channels | Ophthalmology | |
| AG-920 | AG-920 | phase 3 | Nucleoside analog | Ribonucleotide reductase | Oncology |
Therapeutic area mix
- Oncology · 1
- Ophthalmology · 1
Recent regulatory actions (last 90 days)
Upcoming PDUFA dates (next 180 days)
Patent timeline (forward window)
Competitive overlap (companies sharing drug classes)
- Centre Hospitalier Universitaire Saint Pierre · 1 shared drug class
- City of Hope Medical Center · 1 shared drug class
- Cooperative Study Group A for Hematology · 1 shared drug class
- Genzyme, a Sanofi Company · 1 shared drug class
- Hospices Civils de Lyon · 1 shared drug class
- Innovent Biologics (Suzhou) Co. Ltd. · 1 shared drug class
- Nova Scotia Health Authority · 1 shared drug class
- Actuate Therapeutics Inc. · 1 shared drug class
Subscribe to ongoing alerts
Every new pipeline event for American Genomics, LLC:
- American Genomics, LLC pipeline updates — RSS
- American Genomics, LLC pipeline updates — Atom
- American Genomics, LLC pipeline updates — JSON
Cite this brief
Drug Landscape (2026). American Genomics, LLC — Portfolio Competitive Intelligence Brief. https://druglandscape.com/ci/company/american-genomics-llc. Accessed 2026-06-10.